VIDEO: Canadian Physicians on Non-Medical Switching, Biosimilar Naming
December 7, 2017
Margaret McCarthy
FDA Launches Biosimilar Education Site for Prescribers
November 5, 2017
On October 23rd, the FDA launched a robust online resource center aimed at educating prescribers on biosimilars. The website includes fact sheets which explain regulatory terminology such as, “reference product” and “interchangeability”. The fact sheets also detail the biosimilar approval process as well as explain how these medicines are prescribed and substituted. Sections include: Biosimilar and Interchangeable Products; Biosimilar Development, […]
New York Becomes 36th State to Pass Biosimilar Substitution Law
November 5, 2017
On Monday, October 23rd, Governor Andrew Cuomo signed biosimilars legislation (S.4788A/A.7509A) regarding the pharmacy substitution of interchangeable biosimilar medical products—a measure ASBM and others have pursued in New York over the past two years. New York is now the 36th state to pass biosimilars substitution legislation. This law (Chapter 357 of the Laws of 2017) […]
ASBM Presents at 65th WHO Naming Meeting
October 20, 2017
On October 17th, ASBM Chair, Madeline Feldman, M.D., FACR; Advisory Board Chair, Philip Schneider, MS, FASHP; and Executive Director, Michael Reilly, Esq. appeared before the 65th Consultation on International Nonproprietary Names (INN) for Pharmaceutical Substances in Geneva, Switzerland. ASBM has regularly appeared before the INN Consultation since 2013 and continues to advocate for distinguishable […]
Alliance for Safe Biologic Medicines Releases 2017 Canadian Prescriber Survey
October 17, 2017
For Immediate Release ~National survey reveals physician attitudes on key policy issues related to originator biologics and biosimilars ~ Ottawa, Ontario (November 22, 2017) A new national survey conducted by the Alliance for Safe Biologic Medicines (ASBM) found that Canadian physicians overwhelmingly support distinguishable names for all biologics, including biosimilars. Survey results also […]
ASBM Meets with Canadian Health Officials in Ottawa
October 5, 2017
On October 4th, ASBM Executive Director Michael Reilly met with several Canadian health officials in Ottawa to discuss naming and substitution policy, and preview data from ASBM’s Canadian prescriber survey which will be released October 17th at the DIA Canada Annual Meeting in Ottawa. While in Ottawa, Mr. Reilly met with the Minister of Health’s […]
ASBM Presents Poster at ESMO 2017
September 15, 2017
On September 10, 2017 ASBM presented a poster at the European Society of Medical Oncology (ESMO) 2017 Congress which presented perspectives of oncologists from 12 countries regarding biosimilar substitution. Responses were drawn from five recent ASBM surveys which gathered perspectives of more than 1,850 biologic prescribers in Australia, Canada, France, Germany, Italy, Spain, the United Kingdom, and the […]
ASBM Supports WHO Naming Plan in Comments to Australia’s TGA
September 12, 2017
On July 28th, 2017 the Australian Therapeutic Goods Administration (TGA) announced that it was seeking comments from interested parties on the nomenclature for biologic medicines, including biosimilars. In a comment letter dated September 7th, ASBM responded, advocating for distinct naming of all biologics and biosimilars, and urging the TGA to adopt the World Health Organization’s […]
ASBM Shares Australian Data at BMJD Conference
September 8, 2017
At the 5th World Congress on Controversies, Debates & Consensus in Bone, Muscle & Joint Diseases (BMJD), ASBM Steering Committee member Andrew Spiegel, Executive Director of the Global Colon Cancer Association, recently presented, “Real World Considerations for the Use of Biosimilars in Rheumatology: What do Australian Physicians Think?” The conference took place on the Gold Coast […]
ASBM Welcomes Madelaine Feldman as Chair
September 7, 2017
ARLINGTON, VA- In a meeting today, the Alliance for Safe Biologic Medicines (ASBM) introduced rheumatologist Madelaine Feldman, MD, FACR as the organizations incoming chairperson. Dr. Feldman succeeds outgoing chair Harry L. Gewanter, MD, FAAP, FACR, whose 3-year term expired August 31, 2017. Dr. Feldman will be the third chairperson since ASBM was founded in 2010. […]
